Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

[PR Newswire] – PRINCETON, N.J., Feb. 14, 2014 /PRNewswire/ — Soligenix, Inc. (SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unme more

View todays social media effects on XON

View the latest stocks trending across Twitter. Click to view dashboard

See who Intrexon is hiring next, click here to view